NASDAQ:CDTX Cidara Therapeutics (CDTX) Stock Price, News & Analysis → The last Republican president? (From The Freeport Society) (Ad) Free CDTX Stock Alerts $14.16 -0.21 (-1.46%) (As of 06/13/2024 ET) Add Compare Share Share Today's Range$14.00▼$14.4050-Day Range$10.25▼$23.2052-Week Range$10.00▼$24.40Volume26,099 shsAverage Volume50,760 shsMarket Capitalization$64.57 millionP/E RatioN/ADividend YieldN/APrice Target$71.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Cidara Therapeutics alerts: Email Address Cidara Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.25 Rating ScoreUpside/Downside403.2% Upside$71.25 Price TargetShort InterestHealthy2.45% of Float Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment1.33Based on 5 Articles This WeekInsider TradingAcquiring Shares$105,680 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($13.07) to $12.63 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.18 out of 5 starsMedical Sector143rd out of 917 stocksBiological Products, Except Diagnostic Industry15th out of 153 stocks 3.6 Analyst's Opinion Consensus RatingCidara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCidara Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Cidara Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.45% of the float of Cidara Therapeutics has been sold short.Short Interest Ratio / Days to CoverCidara Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cidara Therapeutics has recently increased by 53.21%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCidara Therapeutics does not currently pay a dividend.Dividend GrowthCidara Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCidara Therapeutics has received a 72.74% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for infectious diseases", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Cidara Therapeutics is -0.85. Previous Next 3.0 News and Social Media Coverage News SentimentCidara Therapeutics has a news sentiment score of 1.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Cidara Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for CDTX on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Cidara Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cidara Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $105,680.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.64% of the stock of Cidara Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 35.82% of the stock of Cidara Therapeutics is held by institutions.Read more about Cidara Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cidara Therapeutics are expected to grow in the coming year, from ($13.07) to $12.63 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cidara Therapeutics is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cidara Therapeutics is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Cidara Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyDemocrats’ “break glass for emergency” candidate for 2024Nate Silver has been a celebrity pundit since at least the 2008 election, when he correctly predicted the winner in 49 of 50 states, and nailed all 35 Senate election outcomes. But interestingly, one man reached the same conclusion as Nate Silver a long time ago…For full details, click here. About Cidara Therapeutics Stock (NASDAQ:CDTX)Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.Read More CDTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDTX Stock News HeadlinesJune 12 at 6:26 AM | insidertrades.comCidara Therapeutics, Inc. (NASDAQ:CDTX) CEO Purchases $105,680.00 in StockJune 13 at 6:26 AM | americanbankingnews.comJeffrey Stein Buys 8,000 Shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX) StockMay 30, 2024 | globenewswire.comCidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 ConferenceMay 16, 2024 | markets.businessinsider.comBuy Rating Justified by Cidara Therapeutics’ Upcoming Clinical Trials and Expanding Oncology PipelineMay 16, 2024 | finanznachrichten.deCidara Therapeutics, Inc.: Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing RulesMay 16, 2024 | msn.comCDTX Stock Earnings: Cidara Therapeutics Misses EPS, Misses Revenue for Q1 2024May 15, 2024 | stockhouse.comROSEN, A LEADING NATIONAL FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTXMay 15, 2024 | sfgate.comCidara Therapeutics: Q1 Earnings SnapshotMay 15, 2024 | globenewswire.comCidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 15, 2024 | globenewswire.comCidara Therapeutics Regains Compliance with Nasdaq Continued Listing RulesMay 10, 2024 | prnewswire.comCDTX INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTXApril 26, 2024 | finanznachrichten.deCidara Therapeutics, Inc.: Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024April 26, 2024 | finance.yahoo.comCidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024April 25, 2024 | businesswire.comCDTX LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTXApril 24, 2024 | msn.comCidara Therapeutics shares surge 30% after reacquiring flu treatmentApril 24, 2024 | marketwatch.comCidara Therapeutics To Sell Candidiasis Treatment, Re-acquire Flu AssetApril 24, 2024 | msn.comCidara stock rallies amid $240M private placement, drug updateApril 24, 2024 | globenewswire.comCidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 MillionApril 24, 2024 | globenewswire.comCidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC PipelineApril 23, 2024 | finanznachrichten.deCidara Therapeutics, Inc.: Cidara Therapeutics Announces Receipt of Nasdaq Delinquency NoticeApril 23, 2024 | finanznachrichten.deCidara Therapeutics, Inc.: Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsApril 22, 2024 | investorplace.comCDTX Stock Earnings: Cidara Therapeutics Beats EPS, Beats Revenue for Q4 2023April 22, 2024 | msn.comWhy Cidara Therapeutics (CDTX) Stock Is FallingApril 22, 2024 | globenewswire.comCidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsApril 22, 2024 | globenewswire.comCidara Therapeutics Announces Receipt of Nasdaq Delinquency NoticeSee More Headlines Receive CDTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cidara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/13/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CDTX CUSIPN/A CIK1610618 Webwww.cidara.com Phone(858) 752-6170FaxN/AEmployees69Year FoundedN/APrice Target and Rating Average Stock Price Target$71.25 High Stock Price Target$120.00 Low Stock Price Target$25.00 Potential Upside/Downside+403.2%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($7.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,930,000.00 Net Margins-73.46% Pretax Margin-77.25% Return on Equity-201.62% Return on Assets-54.25% Debt Debt-to-Equity RatioN/A Current Ratio0.72 Quick Ratio0.60 Sales & Book Value Annual Sales$63.90 million Price / Sales1.01 Cash FlowN/A Price / Cash FlowN/A Book Value($1.82) per share Price / Book-7.78Miscellaneous Outstanding Shares4,560,000Free Float4,213,000Market Cap$64.57 million OptionableOptionable Beta1.02 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Jeffrey L. Stein Ph.D. (Age 69)President, CEO & Executive Director Comp: $603.7kMr. Shane M. Ward (Age 49)Chief Legal Officer,Corporate Secretary & COO Comp: $464.54kDr. Taylor Sandison M.D. (Age 52)M.P.H., Chief Medical Officer Comp: $497kDr. Kevin M. Forrest Ph.D. (Age 47)Founder and Chief Strategy Officer Comp: $333.31kDr. Preetam Shah M.B.A. (Age 51)Ph.D., CFO, Chief Business Officer & Principal Accounting Officer Comp: $577.85kMs. Allison Lewis CCPSPHR, Senior Vice President of People & CultureDr. Leslie Tari Ph.D. (Age 56)Chief Scientific Officer Comp: $845.1kMs. Laura A. NavaltaSenior Vice President of Clinical OperationsDr. Nicole Davarpanah J.D.M.D., Senior VP of Translational Research & DevelopmentMore ExecutivesKey CompetitorsNeon TherapeuticsNASDAQ:NTGNApplied Genetic TechnologiesNASDAQ:AGTCInnate PharmaNASDAQ:IPHAMetagenomiNASDAQ:MGXCandel TherapeuticsNASDAQ:CADLView All CompetitorsInsiders & InstitutionsJeffrey SteinBought 8,000 shares on 6/7/2024Total: $105,680.00 ($13.21/share)Alethea Capital Management LLCSold 29,178 shares on 5/17/2024Ownership: 35.055%Tocqueville Asset Management L.P.Bought 68,000 shares on 5/10/2024Ownership: 3.573%Callan Capital LLCSold 8,293 shares on 5/3/2024Ownership: 2.087%Leslie TariSold 1,051 sharesTotal: $14,083.40 ($13.40/share)View All Insider TransactionsView All Institutional Transactions CDTX Stock Analysis - Frequently Asked Questions Should I buy or sell Cidara Therapeutics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last twelve months. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CDTX shares. View CDTX analyst ratings or view top-rated stocks. What is Cidara Therapeutics' stock price target for 2024? 4 Wall Street research analysts have issued 12 month price objectives for Cidara Therapeutics' shares. Their CDTX share price targets range from $25.00 to $120.00. On average, they anticipate the company's share price to reach $71.25 in the next year. This suggests a possible upside of 403.2% from the stock's current price. View analysts price targets for CDTX or view top-rated stocks among Wall Street analysts. How have CDTX shares performed in 2024? Cidara Therapeutics' stock was trading at $15.88 at the beginning of 2024. Since then, CDTX shares have decreased by 10.8% and is now trading at $14.16. View the best growth stocks for 2024 here. Are investors shorting Cidara Therapeutics? Cidara Therapeutics saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 107,400 shares, an increase of 53.2% from the May 15th total of 70,100 shares. Based on an average daily trading volume, of 70,600 shares, the days-to-cover ratio is presently 1.5 days. Currently, 2.5% of the company's stock are short sold. View Cidara Therapeutics' Short Interest. When is Cidara Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our CDTX earnings forecast. How were Cidara Therapeutics' earnings last quarter? Cidara Therapeutics, Inc. (NASDAQ:CDTX) issued its earnings results on Wednesday, May, 15th. The biotechnology company reported ($2.28) EPS for the quarter, missing the consensus estimate of ($1.50) by $0.78. The biotechnology company had revenue of $8.46 million for the quarter, compared to analyst estimates of $14.50 million. Cidara Therapeutics had a negative net margin of 73.46% and a negative trailing twelve-month return on equity of 201.62%. When did Cidara Therapeutics' stock split? Shares of Cidara Therapeutics reverse split on Wednesday, April 24th 2024. The 1-20 reverse split was announced on Wednesday, April 24th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Cidara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cidara Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Verastem (VSTM), Dynavax Technologies (DVAX), Micron Technology (MU), Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE) and Catalyst Pharmaceuticals (CPRX). When did Cidara Therapeutics IPO? Cidara Therapeutics (CDTX) raised $60 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers. Who are Cidara Therapeutics' major shareholders? Cidara Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Alethea Capital Management LLC (35.05%), Tocqueville Asset Management L.P. (3.57%), Callan Capital LLC (2.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brady Johnson, Jeffrey Stein, Leslie Tari, Paul Daruwala, Preetam Shah, Shane Ward, Taylor Sandison and Timothy R Franson. View institutional ownership trends. How do I buy shares of Cidara Therapeutics? Shares of CDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CDTX) was last updated on 6/13/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredLike Investing in Big Tech in the Early 2000s?More than a decade after the first Bitcoin was mined, people are finally realizing something very important......Manward Press | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.